Taking mirtazapine and Mounjaro together: the key facts

Step 1: Understanding what each medicine is doing in your body

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) used primarily for depression and, in some cases, anxiety and sleep disturbance. One of its well-known effects is appetite stimulation, particularly a preference for carbohydrate-rich foods, along with sedation, both of which commonly lead to weight gain over weeks to months of treatment. That weight gain is a recognised clinical concern, and many people on mirtazapine find themselves looking for options to address it.

Mounjaro (tirzepatide) acts on both GIP and GLP-1 receptors, slowing gastric emptying and reducing appetite signals. It is the only dual-agonist weight-loss medicine licensed in the UK. In clinical trials (including SURMOUNT-1, published in the New England Journal of Medicine) participants lost an average of around 20–21% of body weight at the highest dose over 72 weeks. That appetite-suppressing effect is central to how it works, which is precisely where the tension with mirtazapine arises.

Putting these two together means one medicine is actively stimulating appetite while the other is suppressing it. Neither cancels the other out cleanly; the net effect varies between individuals and depends on the mirtazapine dose, the tirzepatide dose reached, and the person's baseline. Your prescriber needs to know you're on mirtazapine before treatment starts, not as a reason to refuse, but as essential context for the clinical review.

Step 2: The gastric-emptying question and oral medicine absorption

A question our prescribers hear regularly is whether tirzepatide changes how mirtazapine is absorbed. It is a fair one. Tirzepatide slows gastric emptying (that is part of its mechanism) and delayed gastric emptying can, in theory, alter the rate at which oral medicines reach the small intestine and enter the bloodstream. The NHS tirzepatide medicines page notes this effect and advises telling your prescriber about all medicines you take, including those for mental health.

In practice, for most oral medicines taken at standard doses, the clinical significance of this slowing is modest. Mirtazapine is absorbed relatively quickly and has a wide therapeutic window, which means small shifts in absorption rate are unlikely to produce dramatic changes in effect. That said, if you notice your mirtazapine feeling less effective (or side effects shifting) after starting tirzepatide, that is worth reporting to whichever clinician manages your antidepressant. It is a monitoring point, not a contraindication.

Tirzepatide is given as a once-weekly subcutaneous injection, so there is no direct pill-on-pill interaction at the point of swallowing. The absorption question concerns only oral medicines taken alongside it, and the timing of mirtazapine (typically at night) is worth flagging if you are also starting treatment that changes gut motility.

Step 3: Communicating between prescribers (and what to tell each one

The single most useful thing you can do before starting Mounjaro is make sure your GP) who likely manages your mirtazapine, knows you are pursuing weight-management treatment. This is standard clinical practice. The NHS England guidance on weight-management injections supports GP notification as part of responsible prescribing, and at nume, GP notification is built into our process in line with GPhC guidance.

Similarly, whoever is reviewing your Mounjaro consultation needs your complete medicine list. Mirtazapine should appear on it, not because it blocks treatment, but because it shapes the clinical picture. Weight gain from psychiatric medicines is a legitimate health concern, and a prescriber who understands your full situation can support you more effectively.

The practical checklist: tell your Mounjaro prescriber about your mirtazapine dose and how long you have been taking it; tell your GP you are starting tirzepatide; report any change in either medicine's apparent effect during the early weeks of treatment. If you are curious about how other medicines interact with tirzepatide, the page on Mounjaro and amlodipine covers a similar process-led approach for a commonly co-prescribed antihypertensive, and the Mounjaro and quetiapine page looks at the interaction with another psychiatric medicine that affects weight.

What this means for your treatment decision

Taking mirtazapine does not automatically make you ineligible for Mounjaro. Many people on antidepressants use tirzepatide for weight management without significant problems. The clinical realities are: one medicine promotes appetite and weight gain, the other reduces both; the combination needs to be declared and reviewed; and your response may be slower or less pronounced than in someone not taking mirtazapine, because the medicines work against each other in that one domain.

Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as hypertension, dyslipidaemia, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber assesses suitability based on the whole picture, not BMI alone. You can read more about what tirzepatide is and how it works on the tirzepatide overview page, or see the broader treatment options at our weight-loss treatment overview. Lifestyle factors are also part of the picture, and if you smoke or vape, it is worth reading up on how Mounjaro and vaping interact before you start treatment, while anyone who drinks regularly will find the guidance on Mounjaro and wine useful for understanding what to consider around alcohol.

Questions about cost context sit separately from this clinical picture. If you want to understand what private treatment involves financially, the Mounjaro prices page sets out the full picture honestly.

If you take mirtazapine and want to explore whether Mounjaro is appropriate for you, the right next step is a clinical conversation. Speak to our prescribers through a free consultation; your medicine list, including mirtazapine, will be reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician reading your answers, not a checklist running automatically.